Abivax (NASDAQ:ABVX) versus Tvardi Therapeutics (NASDAQ:TVRD) Critical Review

Abivax (NASDAQ:ABVX) and Tvardi Therapeutics (NASDAQ:TVRD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Institutional & Insider Ownership

47.9% of Abivax shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 3.1% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Abivax and Tvardi Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	N/A	N/A
Tvardi Therapeutics	-678.79%	-565.83%	-66.71%

Risk and Volatility

Abivax has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Abivax and Tvardi Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	0	0	8	1	3.11
Tvardi Therapeutics	0	0	4	0	3.00

Abivax presently has a consensus price target of $102.14, suggesting a potential upside of 23.30%. Tvardi Therapeutics has a consensus price target of $64.25, suggesting a potential upside of 76.90%. Given Tvardi Therapeutics’ higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Abivax.

Valuation & Earnings

This table compares Abivax and Tvardi Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$190.71 million	N/A	N/A
Tvardi Therapeutics	$7.14 million	47.71	-$70.87 million	N/A	N/A

Tvardi Therapeutics has higher revenue and earnings than Abivax.

Summary

Abivax beats Tvardi Therapeutics on 8 of the 12 factors compared between the two stocks.

About Abivax

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

About Tvardi Therapeutics

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.